drugset
drugset / Trial / NCT02365571

A Study of LY3154207 in Healthy Participants

NCT02365571 ↗

Phase 1 Completed 64 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

This study involves single doses of LY3154207 and will evaluate the effects of LY3154207 on the body. There will be 3 parts to this study. Part A will test single increasing doses of LY3154207 and will last approximately 7 weeks for each participant. Each participant will receive two doses of LY3154207, if part A is completed. Part B will test a single dose of LY3154207 and will last approximately 5 weeks for each participant. Part B includes collecting fluid from the spinal column to measure levels of LY3154207. Part C will include a single dose of LY3154207 given alone and then a second dose given along with itraconazole to look for change in LY3154207 levels. Part C will last about 3 weeks for each participant. Participants may only enroll in 1 of the 3 parts of the study.

Timeline

Start
2015-02
Primary completion
2015-05
Completion
2015-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Mevidalen Small molecule — Oral
Background Itraconazole Small molecule — Oral

Indications

No indication recorded.